Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections. In the past few months, post the outbreak of COVID-19, multiple clinical trials have been initiated on COVID-19 patients in China, Japan and in the US.
“If the clinical trials are successful, Favipiravir could become a potential treatment for COVID-19 patients,” said Sushrut Kulkarni, Executive Vice President – Global R&D, Glenmark Pharmaceuticals.
At 09:16 am, the stock was trading 6 per cent higher at Rs 350 on the BSE, against 2 per cent rise in the S&P BSE Sensex. Around 740,000 shares have changed hands on the counter the BSE and NSE so far.